

Media Contact

Sean Leous

+1.917.715.3765

seanleous@gmail.com**Lumendi/DiLumen Contact**

Donna K. Ramer

+1.917.744.2669

dramer@rxir.com**FOR IMMEDIATE RELEASE****LUMENDI'S DILUMEN I_g[™] ENDOLUMENAL INTERVENTIONAL GRASPER****FOR MINIMALLY INVASIVE ENDOSCOPIC THERAPIES NOW AVAILABLE IN U.S.****Lumendi Submits Premarket Notification to US FDA
For DiLumen C²[™] and the DiLumen I_s[™] as Part of its
Second Generation Endolumenal Interventional Platform**

WESTPORT, CONN, November 10, 2017 – Connecticut-based medical device innovator Lumendi, LLC (<http://www.lumendi.com>) continues to advance minimally invasive endoscopic therapies with the addition of its DiLumen I_g Endolumenal Interventional Grasper that is now available in the United States. The DiLumen I_g is a flexible endoscopic tool intended to grasp and manipulate tissue within the digestive tract under direct endoscopic visualization. In addition, Lumendi has submitted a Premarket Notification to the United States Food and Drug Administration (FDA) for the DiLumen C² and the DiLumen I_s.

DiLumen C² EIP, the second generation Endolumenal Interventional Platform (EIP), is an endoscope accessory intended to ensure complete positioning of an endoscope in the large intestine and assist with optical visualization, diagnosis and endoscopic treatment. The DiLumen I_s Endolumenal Interventional Scissors are a sterile, single-use, disposable monopolar electro-surgical device intended to be used for cutting, dissecting, and cauterizing tissue within the digestive tract during endoscopic procedures. All three devices were developed by Lumendi in collaboration with the Minimally Invasive New Technologies program (MINT) at Weill Cornell Medicine and New York-Presbyterian.

“The DiLumen[™] family of devices facilitates endoscopic treatment of colonic lesions, such as polyps, a common condition that affects millions worldwide, and may replace open surgical or laparoscopic procedures, potentially reducing healthcare costs,” said Dr. Peter Johann, CEO, Lumendi, Ltd.

DiLumen C² EIP is a pioneering technology that stabilizes an endoscope to better facilitate incision-free endolumenal therapeutic procedures. For the first time, two 6mm working channels allow additional therapeutic instruments to be utilized in interventional procedures simultaneously with traditional

endotherapy devices that are used through the endoscope's own working channel. With the introduction of two additional instruments, previously technically difficult and time-consuming procedures can potentially be improved.

The DiLumen I_g and DiLumen I_s will be used in conjunction with the DiLumen C² to expand the capabilities of tissue management necessary to facilitate many intraluminal procedures. Adequate tissue manipulation and traction combined with effective cutting, dissecting and cauterizing continue to be a major challenge for therapeutic procedures in the digestive tract. These new Endoluminal Interventional Instruments are based on Lumendi and MINT's initiative to migrate many gastrointestinal surgeries to endoluminal procedures.

DiLumen C² consists of a single-use, soft flexible sheath that fits over standard and small-diameter endoscopes. The device employs two balloons, one behind the bending section of the endoscope and the second can extend in front of the tip of the endoscope once at the lesion site. When both balloons are deployed and inflated, a stable Therapeutic Zone (TZ™) is created. This TZ™ facilitates more localized insufflation and manipulation of the colon. With the addition of two working channels for DiLumen I_g and DiLumen I_s, tissue can be manipulated, cut and dissected in a way that may better enable access and removal of lesions during endoluminal interventions.

“With the successful introduction of DiLumen EIP earlier this year, DiLumen C², I_g and I_s are the next logical steps in a family of devices to continue the process of enhancing endoscopic treatment. Lumendi continues its commitment to improving endoluminal interventions and is committed to expanding treatments that lead to effective, less-invasive procedures that may ultimately improve patient care,” said Dr. Johann.

About Lumendi, LLC <http://www.lumendi.com> Headquartered in Westport, Connecticut, Lumendi, LLC is a wholly owned subsidiary of Lumendi, Ltd., a privately held innovative, medical device company headquartered in Buckinghamshire, UK. Lumendi is focused on developing, marketing and distributing surgical tools and devices that provide safe, cost-effective solutions for minimally invasive gastrointestinal interventions. Lumendi Ltd. holds a worldwide exclusive license from Cornell University on the DiLumen™ technology.

#